Juniper Pharmaceuticals, Inc. Common Stock
JNP
JNP was delisted on the 13th of August, 2018.
48 hedge funds and large institutions have $44.1M invested in Juniper Pharmaceuticals, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 17 reducing their positions, and 7 closing their positions.
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
2% more funds holding
Funds holding: 47 → 48 (+1)
6% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 17
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14% less capital invested
Capital invested by funds: $51.2M → $44.1M (-$7.15M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.11M |
| 2 |
Renaissance Technologies
New York
|
+$824K |
| 3 |
PCM
Perritt Capital Management
Chicago,
Illinois
|
+$792K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$689K |
| 5 |
AIC
AWM Investment Company
New York
|
+$450K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.67M |
| 2 |
MERSOM
Municipal Employees' Retirement System of Michigan
Lansing,
Michigan
|
-$634K |
| 3 |
B
Bailard
Foster City,
California
|
-$558K |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$476K |
| 5 |
Morgan Stanley
New York
|
-$449K |
JNP Hedge Fund Activity: Q2 2018 in Review
48 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q2 2018, worth a combined $44.1M — down 14% from $51.2M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new JNP positions and 7 closed out — a net gain of 1 holder — while 18 added to existing stakes and 17 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $1.11M. The largest seller was BlackRock, cutting an estimated $1.67M.
- 48 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q2 2018, up from 47 in Q1 2018.
- Funds reported $44.1M of Juniper Pharmaceuticals, Inc. Common Stock stock for Q2 2018, down 14% quarter-over-quarter.
- 8 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q2 2018 and 7 closed out, a net change of +1 holder.
- The largest Juniper Pharmaceuticals, Inc. Common Stock buyer in Q2 2018 was Acadian Asset Management, an estimated $1.11M added.
- The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q2 2018 was BlackRock, an estimated $1.67M sold.
Based on aggregated 13F filings for Q2 2018.